Aimei Health Technology Co. Business Summary

Aimei Health Technology Co., Ltd. (AFJK) operates as a Special Purpose Acquisition Company (SPAC) whose primary business model involves raising capital through an initial public offering to effect a merger, asset acquisition, or similar business combination. As of March 2026, the company is in a late-stage pursuit of a definitive business combination with United Hydrogen Group Inc., a Cayman Islands-based hydrogen energy firm. The company’s revenue is currently non-operational, derived from interest on trust account assets, and it relies on non-interest-bearing promissory notes from its sponsor, Aimei Health Ltd, and United Hydrogen to fund ongoing extension payments. Within the micro-cap shell company landscape, AFJK competes for investor capital and regulatory approval alongside peers such as 1RT Acquisition Corp, A SPAC III Acquisition Corp, and AGBA Group. AFJK distinguishes itself through its persistent extension strategy—having secured its sixteenth monthly extension to April 6, 2026—and its pivot toward the renewable energy sector despite an initial focus on healthcare and biotechnology. The leadership team is led by Junheng Xie, who serves as the Chief Executive Officer, Secretary, and Director. Xie is recognized for his strategic oversight in navigating the complex regulatory requirements of the SPAC lifecycle and managing the transition toward the hydrogen energy sector. He is supported by Heung Ming (Herman) Wong, the Chief Financial Officer and Director, who brings extensive expertise in financial reporting, auditing, and capital management, having previously held senior roles and independent directorships for various international entities. The board’s stability is reinforced by the financial backing of the sponsor, Aimei Health Ltd, and strategic alignment with United Hydrogen Group Inc., which has co-funded recent trust account deposits. This collaborative leadership structure is designed to mitigate the risks associated with the company’s extended pre-merger phase and ensure the successful closing of the pending business combination.